Benign Conditions

Benign Prostatic Hyperplasia

Bladder Cancer

Female Urology

Genitourinary Cancers

Genomic Testing

Hormone Therapy

Kidney Cancer

Challenging Anatomy

Innovative Techniques

Laser Lithotripsy

PCNL Tech & Devices

Ureteroscopy Tech & Devices

Kidney Stones

Men's Health

Next-Generation Imaging

Voiding Dysfunction

OAB and Incontinence

Pediatrics

Controveries in Urologic Cancer

Drug Therapy

Prostate Cancer

Sexual Dysfunction

UTUC

Cosmetic Surgery

Urologic Surgery

Business

Practice Management

Malpractice Consult

Health Law & Policy

Media

Case-Based Peer Perspectives

Investigator Perspectives 

Medical World News

Podcasts

Urology Medical Perspectives

UTv Videos

Peer Exchange

Special Report

Virtual Tumor Board

Insights

Medcast

Peers & Perspectives

Conferences

Conference Listing

Conference Previews 

Conference Recaps

Publications

Urology Times Journal

Editorial Advisory Board

Urologists in Cancer Care

Supplements and Featured Publications

Clinical Forums Recaps

CME/CE

Resources

Begin Your Journey: Tackling Burnout

Live Events

Disease Staes

Interactive Tools

Job Board

Partners

Subscribe

Articles

"At ASCO GU, we presented the final analysis of the study, which confirmed the superiority of a combination over the TKI monotherapy in terms of both progression-free survival as well as overall survival," says Camillo Porta, MD. 

Camillo Porta, MD, offers key takeaways from CheckMate 9ER trial in renal cell carcinoma

YOLT-203 was granted an Orphan Drug Designation and a Rare Pediatric Disease Designation in September 2024.

YOLT-203 shows promise in early phase 1 trial for primary hyperoxaluria 1

Myriad is planning to launch its first AI-driven prostate cancer clinical test later this year.

Myriad Genetics, PATHOMIQ enter agreement for usage of AI platform for prostate cancer

The trial plans to enroll up to 80 adult patients with mCRPC who have progressed on prior systemic therapies.

Phase 1/2 trial launches of first-in-class RIPTAC therapeutic in mCRPC

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do not sell my Personnal Information

Urology Times | News & Insights for Urologists & Health Professionals

Facebook

LinkedIn

Spotlight

Peers and Perspectives

Clinical

1rem

View

Advancing Patient Care in Non–Muscle-Invasive Bladder Cancer

Video Series

Videos

A panelist discusses how identifying intermediate-risk patients, managing disease heterogeneity in non–muscle-invasive bladder cancer, and addressing long-term care needs present key challenges in patient care while highlighting recent treatment advances that offer promising solutions.

Episode 1: Advancing Patient Care in Non–Muscle-Invasive Bladder Cancer

Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC 

Episode 2 Video: Identifying Patients with Intermediate Risk in NMIBC 

Panelists examine disease heterogeneity in NMIBC and discuss a balanced treatment approach that prioritizes patient quality of life and surgery effectiveness.

Episode 3 Podcast: Treatment Strategies to Tackle NMIBC Heterogeneity

Episode 3 Video: Treatment Strategies to Tackle NMIBC Heterogeneity

Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management